Cidara Therapeutics, Inc.

DB:20D0 Stock Report

Market Cap: €244.8m

Cidara Therapeutics Management

Management criteria checks 2/4

Cidara Therapeutics' CEO is Jeff Stein, appointed in Jan 2014, has a tenure of 11.33 years. total yearly compensation is $5.97M, comprised of 10.4% salary and 89.6% bonuses, including company stock and options. directly owns 0.73% of the company’s shares, worth €1.79M. The average tenure of the management team and the board of directors is 3.1 years and 4.3 years respectively.

Key information

Jeff Stein

Chief executive officer

US$6.0m

Total compensation

CEO salary percentage10.35%
CEO tenure11.3yrs
CEO ownership0.7%
Management average tenure3.1yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jeff Stein's remuneration changed compared to Cidara Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$186m

Dec 31 2024US$6mUS$618k

-US$170m

Sep 30 2024n/an/a

-US$126m

Jun 30 2024n/an/a

-US$114m

Mar 31 2024n/an/a

-US$26m

Dec 31 2023US$2mUS$594k

-US$25m

Sep 30 2023n/an/a

-US$34m

Jun 30 2023n/an/a

-US$18m

Mar 31 2023n/an/a

-US$22m

Dec 31 2022US$1mUS$566k

-US$22m

Sep 30 2022n/an/a

-US$33m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$2mUS$566k

-US$42m

Sep 30 2021n/an/a

-US$47m

Jun 30 2021n/an/a

-US$47m

Mar 31 2021n/an/a

-US$74m

Dec 31 2020US$1mUS$542k

-US$75m

Sep 30 2020n/an/a

-US$67m

Jun 30 2020n/an/a

-US$47m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$1mUS$526k

-US$41m

Sep 30 2019n/an/a

-US$39m

Jun 30 2019n/an/a

-US$56m

Mar 31 2019n/an/a

-US$69m

Dec 31 2018US$1mUS$501k

-US$69m

Compensation vs Market: Jeff's total compensation ($USD5.97M) is above average for companies of similar size in the German market ($USD801.74K).

Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.

CEO

Jeff Stein (69 yo)

11.3yrs

Tenure

US$5,965,903

Compensation

Dr. Jeffrey L. Stein, Ph D., also known as Jeff, has been the Chief Executive Officer, President and Executive Director of Cidara Therapeutics, Inc. since January 2014. Dr. Stein served as Principal Financ...

Leadership Team

NamePositionTenureCompensationOwnership
Jeffrey Stein
President11.3yrsUS$5.97m0.73%
€ 1.8m
Leslie Tari
Chief Scientific Officer6.2yrsUS$2.04m0.10%
€ 247.6k
Kevin Forrest
Founder & Chief Strategy Officerno dataUS$613.24kno data
Frank Karbe
Chief Financial Officerless than a yearno datano data
Shane Ward
COO & Corporate Secretary3.8yrsUS$929.86k0%
€ 0
Preetam Shah
Principal Accounting Officer3.1yrsUS$683.71k0%
€ 0
Allison Lewis
Senior Vice President of People & Culture4.3yrsno datano data
Nicole Davarpanah
Chief Medical Officer1.8yrsno data0.20%
€ 484.7k
Jim Beitel
Chief Business Officerless than a yearno datano data
Corrina Pavetto
Senior Vice President of Clinical Developmentno datano datano data

3.1yrs

Average Tenure

53.5yo

Average Age

Experienced Management: 20D0's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jeffrey Stein
President11.3yrsUS$5.97m0.73%
€ 1.8m
Daniel Burgess
Independent Chairman of the Board11.1yrsUS$451.51k0.0014%
€ 3.4k
Theodore Schroeder
Independent Director11.1yrsUS$423.51k0%
€ 0
Rick Bright
Member of Scientific Advisory Boardless than a yearno datano data
Frederick Hayden
Member of the Scientific Advisory Board4.8yrsno datano data
Bonnie Bassler
Independent Director4.3yrsUS$331.56k0.00014%
€ 342.7
Carin Canale-Theakston
Independent Director4.3yrsUS$332.29k0%
€ 0
Chrysa Mineo
Independent Director7.2yrsUS$391.10k0%
€ 0
Ryan Spencer
Independent Director1.1yrsUS$85.52k0%
€ 0
James Merson
Independent Director1.1yrsUS$88.26k0%
€ 0
Mario Barro
Member of Scientific Advisory Boardless than a yearno datano data
Philip Krause
Member of Scientific Advisory Boardless than a yearno datano data

4.3yrs

Average Tenure

62yo

Average Age

Experienced Board: 20D0's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/16 11:25
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cidara Therapeutics, Inc. is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Timothy ChiangBTIG
Chiara RussoCantor Fitzgerald & Co.
Eric SchmidtCantor Fitzgerald & Co.